Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Der
Go back to Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Der| (NASDAQ: PVLA) | Delayed: 118.84 +5.74 (5.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $113.10 | 52 Week High | $ | |||
| Open | $115.29 | 52 Week Low | $ | |||
| Day High | $120.88 | P/E | N/A | |||
| Day Low | $114.55 | EPS | $ | |||
| Volume | 231,425 | |||||
